MedPath

CYTOPEUTICS SDN. BHD.

🇲🇾Malaysia
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 1
1 (33.3%)

UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)

Phase 2
Recruiting
Conditions
Acute Ischemic Stroke
First Posted Date
2023-11-13
Last Posted Date
2024-01-03
Lead Sponsor
Cytopeutics Sdn. Bhd.
Target Recruit Count
80
Registration Number
NCT06129175
Locations
🇲🇾

Hospital Canselor Tuanku Muhriz UKM, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia

Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury

Phase 2
Completed
Conditions
Osteoarthritis, Knee
First Posted Date
2021-08-23
Last Posted Date
2024-01-03
Lead Sponsor
Cytopeutics Sdn. Bhd.
Target Recruit Count
28
Registration Number
NCT05016011
Locations
🇲🇾

Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM-UKM), Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia

UCMSCs as Front-line Approach of Treatment for Patients With aGVHD

Phase 1
Active, not recruiting
Conditions
Acute-graft-versus-host Disease
First Posted Date
2019-02-20
Last Posted Date
2024-01-03
Lead Sponsor
Cytopeutics Sdn. Bhd.
Target Recruit Count
26
Registration Number
NCT03847844
Locations
🇲🇾

Hospital Ampang, Ampang, Selangor, Malaysia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.